A Phase I, Randomized, Single-center, 3-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of CC 99677 in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2019
Price : $35 *
At a glance
- Drugs CC-99677 (Primary)
- Indications Inflammation
- Focus Adverse reactions; First in man
- Sponsors Celgene Corporation
- 12 Aug 2019 Planned End Date changed from 31 May 2019 to 30 Nov 2019.
- 12 Aug 2019 Planned primary completion date changed from 31 May 2019 to 30 Nov 2019.
- 20 Jun 2018 New trial record